ERBB2 and breast cancer: The NeoMONARCH open-label Phase II study randomized 224 postmenopausal stage I-IIIB HR+/HER2- breast cancer patients to two weeks of combination (abemaciclib plus anastrozole), abemaciclib and anastrozole monotherapies, followed by 14 weeks of combination treatment.